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Though colon cancer is the second leading cause of cancer deaths in the US, it is entirely preventable through early screening to
detect andremove adenomatous polyps.Colonoscopyhaslongbeen regarded asthe“gold standard”but isexpensive, invasive,and
uncomfortable, and only about half those considered at risk for colon cancer currently submit to colonoscopy or to less reliable
alternatives such as fecal occult blood test. Here we describe the use of gene expression analysis to detect altered expression of
certain genes associated with not only colon cancer but also polyps. The analysis can be performed on rectal swabs, with specimens
providedinaroutinedoctor’soﬃcevisit.Theexistence ofthischeapandsimpletest,togetherwithanactive programtoencourage
individuals to submit to screening, could help eradicate colon cancer.
1.Introduction
Colorectal cancer is the third most common cancer in the
US and continues to be the second leading cause of cancer
deaths. Each year, about 150,000 new cases will be diagnosed
and 50,000 patients will die of this disease. These data have
not changed much despite increased eﬀorts over the last
decade to persuade individuals at risk to undergo screening.
In the US, colonoscopy remains the so-called gold standard,
because it can detect not only early colorectal cancer but
also signiﬁcant precancerous polyps such as the serrated
adenomas or the villotubular adenomas, which can be re-
moved by the same procedure. In principle, then, colon can-
cer is entirely preventable.
Colonoscopy is expensive and invasive, however, and re-
quires a colon preparation prior to surgery. Individuals with-
out health insurance, and of lower socioeconomic status, are
less likely to have a colonoscopy. Some of these individuals
opt for other recommended screening procedures, including
combination of fecal occult test for blood in the stool
annually or ﬂexible sigmoidoscopy every 5 years. These tests
are also more common in many countries outside the US,
due to ﬁnancial limitations. Lately, with the US in recession
and major cutbacks proposed on health care expenditures,
even expert gastroenterologists have suggested that perhaps
colonoscopyshouldnotbethegoldstandardforcoloncancer
screening [1] .I na n yc a s e ,c u r r e n t l yo n l ya b o u t5 5 %o f
recommended individuals, including all individuals over 50
years old, are screened by any procedure.
In February of 2010, the National Institutes of Health
(NIH) organized a Consensus Conference, bringing together
with a public representative a group of experts represent-
ing the ﬁelds of cancer surveillance, health services research,
community-based research, informed decision-making, ac-
cess to care, healthcare policy, health communication, health
economics, health disparities, epidemiology, statistics, tho-
racic radiology, internal medicine, gastroenterology, public
health, end-of-life care [2]. The conclusions at this Con-
sensus Conference will have far-reaching consequences on
how the US will try to cope with the challenges of early
detection of colorectal cancer with improved 5-year survival
rates. Noting that the low screening rate in this country is the
major obstacle to prevention of colon cancer, the Conference
suggested the following ways to improve this rate:
(1) eliminate ﬁnancial barriers to colonoscopy;
(2) promoteinterventionsthathavebeenshowntobeef-
fective in persuading people to be screened;2 ISRN Gastroenterology
(3) develop more eﬀective educational programs for tar-
geted patient groups, such as those who lack health
insurance and/or are of lower socioeconomic status;
(4) implement approaches that will ensure appropriate
followup of positive screening results;
(5) develop systems to ensure the high quality of colorec-
tal cancer screening programs;
(6) conduct studies to determine the comparative eﬀec-
tiveness of the various colorectal cancer screening
methods currently in use.
The development of a cheaper and less invasive screening
procedure that could detect both cancer and precancerous
polyps as reliably as colonoscopy would address most of
these issues. In particular, a cheap, simple, noninvasive
test that could be performed by any physician would re-
move the ﬁnancial and emotional barriers to screening. Sev-
eral possible alternatives are currently being researched, in-
cluding and stool tests for DNA mutations associated with
colon cancer [3, 4] and various types of blood tests for colon
cancer markers [5]. The capsule camera approach, while rel-
atively expensive and also requiring a colon prep, is another
less invasive alternative to colonoscopy [6]. While all of these
approaches show some promise, none of them to date has
achieved a degree of sensitivity or speciﬁcity equal to that of
colonoscopy.
In this paper, we will discuss our research to develop a
rectal swab test, without the need for a bowel preparation.
Those individuals testing positive will be recommended for
immediate diagnostic colonoscopy to remove any large pre-
cancerous polyps or resect an early cancer. Individuals re-
peatedly testing negative in the swab test should not require
colonoscopy. Our aim is that the high sensitivity and spec-
iﬁcity of this test will compare favorably with all existing
screening modalities.
2.MaterialsandMethods
2.1. Animal and Human Tissues. Tissues examined in our
studies included the entire colon of mouse (C57BL/6J-
min/+ mice, and the wildtype littermates were obtained
from Jackson Laboratory, Bar Harbor, ME, USA), which
was removed from the animals, opened longitudinally, and
washed in cold phosphate-buﬀered saline, polyps and mor-
phologically normal colon tissue removed from patients
undergoing colonoscopy at the California Paciﬁc Medical
Center (CPMC), and colon cancer removed from patients
undergoing surgical resection at CPMC. The appropriate
procedure for obtaining formed consent was followed for all
individuals participating in these studies. All samples from
human patients were snap-frozen on dry ice as soon as pos-
sible within 30 minutes of surgery, then taken immediately
to the laboratory for RNA preparation (see below).
2.2. Extraction and Preparation of RNA. Total RNA was
extracted from tissues using RNAeasy kits from Qiagen
(Valencia, California). RNA samples were treated with
RNase-free DNase to remove any genomic DNA contamina-
tion and were reverse-transcribed. Fifty ng of cDNA from
each sample were used as template for PCR ampliﬁcation
with speciﬁc oligonucleotide primers using the Applied Bio-
systems 5700 Sequence Detection System (PE Applied Bio-
systems, Foster City, California). PCR reactions were per-
formed according to the manufacturer’s instructions using
the SYBR Green PCR Core Kit (PE Applied Biosystems,
Foster City, California).
2.3. Analysis of Gene Expression. We analyzed ﬁfteen genes,
all of which have previously been shown to be altered in
expressioninhumancoloncancer.Theyfallintofourgroups,
including those involved in the (1) APC/β-catenin pathway,
including c-myc, cyclin D1, and proliferating peroxisome
activating receptor (PPARα)[ 7, 8]; (2) NF-κB/inﬂammation
pathway, including growth-related oncogene (Gro-α), osteo-
pontin (OPN), and colony-stimulating factor (M-CSF-1)
[9], cyclooxygenase (COX-)1 and 2, Gro-γ (or its mouse
homolog,macrophageinﬂammatoryprotein-2(MIP-2)),in-
terleukin-8 (IL-8) (or its mouse homolog, stroma-derived
factor (SDF-1)), and the cytokine receptor CXCR2; (3) cell
cycle/transcription factor, including p21cip/waf1,c y c l i nD 1 ,c -
myc, PPARα, δ, γ [10, 11]; (4) cell communication signals,
including IL-8, PPARα, δ, γ CXCR2, CD44, and OPN. Most
of these genes have been reported to be upregulated in
human colon cancers, though some, such as the p21cip/waf1,
are downregulated.
Speciﬁc primers against each gene were designed using
the Primer Express Software (PE Applied Biosystems, Foster
City, California). Primer length was 21–27 nucleotides, with
a theoretical Tm of 58–60◦C. The amplicon size ranged from
66 to 150bp. Primers were designed to amplify only cDNA
template but not genomic DNA template when possible. The
speciﬁcities of the primers used were demonstrated by the
appearance of a single product on 10% polyacrylamide gel
electrophoresis and a single dissociation curve of the PCR
product.
All the cDNA samples were tested for genomic DNA con-
tamination by using primers for β-actin genomic DNA. Us-
ing these primers, PCR products derived from the genomic
D N Ah a v ead i ﬀerent Tm and length from the PCR product
derived from cDNA. Only cDNA samples without genomic
DNA contamination were used.
For quantitation of gene expression, the ﬂuorescence
of the SYBR Green dye bound to the PCR products was
measured after each cycle and the cycle numbers were re-
corded when the accumulated signals crossed an arbitrary
threshold (CT value). In order to normalize this value, a
ΔCT value was determined as the diﬀerence between the CT
value for each gene and the CT value for β-actin, which was
determined in each experiment and shown not to vary sig-
niﬁcantly under the diﬀerent experimental conditions used
in this study. For each gene, a ΔΔCT value was deter-
mined as the diﬀerence between the ΔCT value for each in-
dividual sample and the average ΔCT value for this gene
obtained from the control (wildtype) samples. These ΔΔCT
values were then used to calculate relative gene expressionISRN Gastroenterology 3
values as described (Applied Biosystems, User Bulletin no. 2,
December 11, 1997).
2.4. Statistical Analysis. We used the Wilks lambda criterion
for a multivariate analysis of variance (MANOVA) to com-
pare the patterns of expression levels of several genes from
cancer versus normal subjects. This test takes into account
correlations among gene expression levels and controls the
false positive rate by testing the global hypothesis of no dif-
ferencesingeneexpressionsbetweencancerandnormalsub-
jects. If the test was signiﬁcant; that is, there was evidence
that expression patterns diﬀer, then we used univariate t-
tests to determine which genes were contributing to the
global diﬀerence and which were not. All statistical tests
were carried out on log (base 2) of the gene expression data
since this transformation is required to achieve normal dis-
tribution of values.
In some studies, we also determined the Mahalanobis
distance (M-dist). This measure summarizes, in a single
number, the diﬀerences in a pattern of gene expression, for
any individual against the average of a pool of individuals,
taking into account variability of each gene’s expression and
correlations among pairs of genes. It is thus well suited both
for comparing a control population with an experimental
group,suchasindividualswithcancer,aswellasdetermining
the degree of similarity or ﬁt that an individual of unknown
characteristics has to a well-characterized group. The latter is
what allows M-dist to be used to determine how signiﬁcantly
an individual value diﬀers from a group of controls, which is
necessary in screening.
To perform the calculations, ﬁrst, for each control biopsy
(total of 105), we calculated its M-dist from the multivariate
mean of the other 104 control biopsies. We plotted ordered
M-dist for the 105 control biopsies against the theoretic ex-
pected order statistics for the appropriate chi-squared dis-
tribution, to verify that control gene expression values (log
base 2) were multivariate normal. Then we computed an
M-dist for the gene expression data for each biopsy from
each individual with polyps, where M-dist measured the in-
dividual’s multivariate distance (i.e., diﬀerence in pattern of
expression) from the pooled mean of the 105 control bio-
psies.
M-dist can be converted to P values by reference to a
chi-squared distribution with degrees of freedom equal to
the number of variables (i.e., genes). Using this approach,
one can determine an upper bound for the normals, at
any arbitrary level of signiﬁcance, such as the 95th or 99th
percentile. This allows analysis of signiﬁcance of gene ex-
pression values of any individual experimental subject as
compared to the pool of controls.
3. Results andDiscussion
Gene expression changes in colon mucosa of a mouse model
of colon cancer. We began our studies by examining the
APCmin mouse[12].Theseanimalsareengineeredtocontain
a mutant form of the human gene adenomatous polyposis
coli (APC). As in humans with this mutant gene, these mice
develop numerous intestinal polyps at a relatively young age;
Table 1: Relative gene expression levels in colon polyps of APCmin
mice (mean ± SE).
No. Gene Wildtype littermate Individual polyp P value
1O P N 1 .62 ±0.60 430.38 ±125.24 <0.01
2 MIP-2 1.74 ±1.60 202.74 ±43.40 <0.001
3G r o - α 1.40 ±0.32 122.48 ±18.97 <0.001
4C X C R 2 1 .41 ±0.35 104.51 ±23.31 <0.001
5 COX-2 1.41 ±0.25 81.64 ±16.36 <0.001
6C y c l i n D 1 1 .34 ±0.34 19.48 ±2.67 <0.001
7S D F - 1 1 .23 ±0.34 11.02 ±2.45 <0.01
8c - m y c 1 .09 ±0.18 6.49 ±0.96 <0.001
9M - C S F 1 1 .05 ±0.15 4.26 ±1.60 NS
10 CD44V6 1.17 ±0.28 3.78 ±0.61 <0.01
11 COX-1 1.07 ±0.15 3.24 ±0.60 <0.01
12 PPAR-γ 1.13 ±0.22 0.86 ±0.24 NS
13 p21cip/waf1 1.11 ±0.17 0.51 ±0.07 <0.05
14 PPAR-δ 1.16 ±0.27 0.44 ±0.05 <0.05
15 PPAR-α 1.04 ±0.12 0.17 ±0.03 <0.001
Gene expression levels were determined using RT-PCR. In no. 1∼5, n = 13
in the wildtype littermate group; n = 14, in the individual polyp group; in
no. 6∼15, n = 6 in the wildtype littermate group; n = 10 in the individual
polyp group. Signiﬁcance was determined by t-test.
some of which will progress to locally invasive carcinomas
[13]. We ﬁrst removed polyps from these animals and
analyzed them for expression of ﬁfteen genes.
When we analyzed polyps that were removed from
these animals at various ages, we observed a wide range of
expression levels of these genes, ranging from several that
were dramatically upregulated to several that were modestly
upregulated, others that exhibited no signiﬁcant change
in expression level, and several that were downregulated.
As shown in Table 1, ﬁve genes—COX-2, GRO-α,C X C R 2 ,
OPN, and MIP-2—exhibited a particularly high degree of
altered expression in adenomatous polyps (P<0.001). All
of these genes have also been reported to be upregulated in
human colon cancer or other cancers, though not to such a
high degree [11, 14–16].
In studies like this that have been carried out previously
by other investigators, it has been assumed that gene
expressionvaluesinnormalappearingmucosainthemutant
mice, in regions away from the polyp, would be similar to
those in control mice without polyps. However, when we
actually compared the two, we found it was not the case. In
these experiments, polyps were removed from the intestines
of APCmin mice at three diﬀerent ages—6, 13, and 23 weeks
old—and the polyp-free intestines compared with normal
colon tissue from wildtype littermates. The intestines were
divided into six equal segments of approximately 1.5cm in
length, colonic mucosa was isolated, and the expression of
the ﬁve genes most altered in polyps analyzed.
While the expression levels of a particular gene in a
particularsegmentataparticularageshowedlittlevariability
from one wildtype animal to another, there was considerable
variation in values for APCmin mice. As shown in Table 2,
all of these genes except OPN were signiﬁcantly upregulated,4 ISRN Gastroenterology
Table 2: Multivariate analysis of gene expression in normal-ap-
pearing colon mucosa of 23 week old APCmin mice, as compared
to colon mucosa of normal mice.
Colon segment
G e n e123456
COX-2 ++ ++++ + ++++ + +++
CXCR-2 + ++ — ++ + ++++
MIP-2 ++ ++ — ++ + +++
Gro-α — + — — + +++
O P N ——————
Colons were removed from animals and any polyps removed. The colons
were then divided into 6 segments, colon mucosa isolated, and gene ex-
pression determined as described in the Material and Methods section, with
values for APCmin mice compared to those for wildtype mice. Multivariate
analysis was performed on these values as described in the Material and
Methods section, in which the signiﬁcance of the diﬀerence in expression
between APCmin and wildtype mice was determined for each gene in the
presence of all the other genes. For this analysis, 6 mice were used for each
group (APCmin and wildtype), and 1 mucosa sample analyzed per segment
per mouse, +: P<0.05; ++: P<0.01; +++: P<0.001; ++++: P<0.0001.
relative to wildtype mucosa, in at least some segments. Of
particular interest was that the distribution of these meta-
bolic alterations was not correlated with the presence of
polyp (data not shown, but see Figure 1, below); that is, the
greatest diﬀerences in expression were not necessarily in a
region that had been close to the location of a polyp. This
ﬁndingsuggeststhattheobservedchangesingeneexpression
were not the result of a ﬁeld eﬀect, caused, for example, by
escape of altered cells from the polyps, but were intrinsic
to the morphologically normal cells of the colon where they
were detected.
3.1. Gene Expression Changes in Cancer and Normal Mucosa
of Human Patients. We next analyzed colon samples from
human patients who had previously undergone surgery to
remove colon carcinomas [8]. As noted earlier, all the genes
we analyzed in mouse have been shown by other laboratories
to be diﬀerently regulated (up or down) in human colon
cancers. Such studies, however, have generally assumed that
morphologicallynormalcolonmucosaadjacenttothetumor
is metabolically normal and, indeed, have used such tissue
as a baseline for comparison. Because of our ﬁndings with
APCmin mice, we were interested in determining whether
this assumption is actually valid or whether altered gene ex-
pression proﬁles exist even in morphologically normal colon
of cancer patients. For this study, we thus compared gene
expressionlevelsinmorphologicallynormalappearingcolon
mucosa from cancer patients with levels in mucosa from
noncancer patients. In both cases, the normal appearing
mucosa was removed as biopsies during a colonoscopy. We
analyzed two sets of data, one set consisting of samples from
patients with cancer in the sigmoidal-rectal region and the
other samples from patients with cancer in the ascending
colon region. In both studies, we examined expression levels
of the same ﬁfteen genes that were analyzed in APCmin mice,
except for Gro-γ, the human analog of MIP-2 in mouse, and
IL-8, a close relative of SDF-1 in mouse.
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Figure 1: Distribution of IL-8 expression in sigmoidal-rectal colon
ofasinglecancerpatient.Thepatienthadacancerinthesigmoidal-
rectal colon, as indicated by the spot with jagged edges. Locations
of other mucosa samples removed for analysis are indicated by
the circular spots. Levels of IL-8 expression in each sample were
determined by RT-PCR and are indicated roughly by color coding,
asshownintheFigure.ThemeanlevelofexpressionofIL-8incolon
mucosa of noncancer patients was 2.25 (as shown in Table 3).
As with the mice, we observed great variability of ex-
pression levels in morphologically normal mucosa from can-
cer patients (Table 3). However, expression levels for several
genes tended to be much higher for some samples from
cancer patients than for any colon mucosal samples from
noncancer patients. For example, four of the genes that
were signiﬁcantly upregulated in normal appearing mucosa
of APCmin mice—CXCR2, GRO-α, COX-2 and OPN—were
upregulated in normal appearing mucosa of some cancer
patients to levels of 50–200 times relative to that of most val-
ues in noncancer patients. In addition, in some cancer pa-
tients, PPAR α, δ,a n dγ were downregulated ﬁfty to one
hundred times relative to normal colon mucosal biopsies
from noncancer patients.
All together, seven genes appeared to be signiﬁcantly up-
regulated in morphologically normal mucosa of sigmoidal-
rectal cancer patients, relative to mucosa of noncancer pa-
tients: M-CSF-1, OPN, IL-8, COX-2, CXCR2, p21, and
CD44. An additional two genes—PPAR δ and γ—were
shown to be signiﬁcantly downregulated (Table 3). Quite
similar results were obtained for ascending colon. Six of
the seven genes signiﬁcantly upregulated in sigmoidal-rectal
mucosa were also upregulated in ascending colon—M-CSF-
1, OPN,IL-8, COX-2, CXCR2, andCD44—along withCOX-
1. Likewise, the same two genes, PPAR δ and γ, were signiﬁ-
cantlydownregulatedinexpressioninsigmoidal-rectalcolon
and were also downregulated in ascending colon (Table 3).
The samples of normal-appearing mucosa from cancer
patients that were analyzed for the data in Table 3 were taken
fromallareasofthesurgicalsection.Figure 1showsschemat-
ically the distribution of samples from a single cancer patient
and indicates the approximate expression level in each
sample of a single gene, IL-8. It can be seen that there was no
correlation of expression level with distance from the cancer,
just as there was no correlation of expression level withISRN Gastroenterology 5
Table 3: Multivariate analysis of gene expression in normal appearing colon mucosa of colon of individuals with cancer and controls.
(a) Sigmoidal-rectal colon
Normal subjects Cancer patients
Gene Mean + SD Range P value
1 CXCR2 1.30 ± 1.11 0.81–210.11 <0.01
2G r o - α 2.93 ± 6.93 0.78–104.69 NS
3I L - 8 2 . 2 5 ± 2.63 1.22–82.14 0.0001
4 COX-2 1.80 ± 2.63 0.91–66.26 0.001
5 OPN 1.55 ± 2.04 0.94–58.08 0.0001
6G r o - γ 1.92 ± 3.34 0.80–36.50 NS
7 M-CSF-1 1.54 ± 1.40 1.54–30.70 0.0001
8 COX-1 1.22 ± 0.87 0.12–9.58 NS
9C D 4 4 1 . 1 2 ± 0.56 0.54–6.52 <0.05
10 c-MYC 1.24 ± 0.82 0.12–4.76 NS
11 Cyclin D 1.28 ± 0.84 0.43–4.44 NS
12 PPAR-α 1.10 ± 0.62 0.02–2.87 NS
13 PPAR-δ 1.15 + 0.55 0.023–1.90 <0.01
14 P21 1.04 + 0.29 0.40–1.68 <0.01
15 PPAR-γ 1.07 + 0.40 0.01–1.28 <0.01
(b) Ascending colon
Normal subjects Cancer patients
Gene Mean + SD Range P value
1 CXCR2 1.32 + 1.08 1.90–90.20 <0.05
2G r o - α 1.60 + 2.08 0.46–29.90 NS
3 IL-8 1.66 + 1.62 1.32–182.66 <0.05
4 COX-2 1.84 + 3.04 2.96–152.50 0.0001
5 OPN 1.53 + 1.31 9.24–152.98 0.0001
6G r o - γ 1.40 + 1.41 0.63–11.16 NS
7 M-CSF-1 1.68 + 1.62 4.01–40. 19 0.0001
8 COX-1 1.17 + 0.75 0.84–44.90 <0.001
9 CD44 1.11 + 0.51 0.99–13.63 0.0001
10 c-MYC 1.16 + 0.63 0.39–10.82 NS
11 Cyclin D 1.38 + 1.08 0.12–13.15 NS
12 PPAR-α 1.16 + 0.58 0.22–4.09 NS
13 PPAR-δ 1.13 + 0.55 0.02–7.08 <0.05
14 p21 1.09 + 0.40 0.04–2.66 NS
15 PPAR-g 1.08 + 0.42 0.01–1.14 0.01
Colon mucosa samples were isolated from (a) the sigmoidal-rectal region of noncancer subjects (78 samples from 12 individuals) and from the adjacent
normal mucosa of patients with sigmoidal-rectal cancer (62 samples from 5 patients); or (b) from the ascending region of noncancer subjects (39
samples from 11 individuals) and from the adjacent normal mucosa of patients with ascending colon cancer (65 samples from 4 patients). Samples were
analyzedforgeneexpressionasdescribedintheMaterialandMethodssection.Means+standarddeviationsaregivenfornoncancersubjects; rangesare
given for cancer patients. Multivariate analysis was then performed on each gene taken in relation to all the other genes, to determine the signiﬁcance
of the diﬀerence between cancer and noncancer individuals. NS, not signiﬁcant at P<0.05 level.
distance from polyp in APCmin mice. A relatively high level
of IL-8 expression might be found distant from the tumor,
while a low level might be found closer to the tumor. Similar
results were obtained with other diﬀerently regulated genes.
These observations strongly suggest that the diﬀerently
regulated areas of gene expression in normal-appearing
colon mucosa of cancer patients did not result from a ﬁeld
eﬀect of spreading cells from the original cancer. It appears
that, in individuals with cancer, the normal-appearing colon
mucosa has developed abnormalities that can be detected
at the molecular level. Polley et al. [17] have conﬁrmed the
existence of similar changes using protein expression. For
example, they reported changes in expression of more than
two hundred diﬀerent proteins when mucosa of individuals
with no polyps were compared with mucosa of individu-
als with polyps. Subsequent studies studying methylation6 ISRN Gastroenterology
patterns of several genes in mucosa found diﬀerences associ-
ated with both aging and the development of carcinogenesis
[18, 19], which could be critical steps in the conversion of
normal mucosa to polyps and cancer [20]. It is also relevant
to note that a study by Øgreid and Hamre [21] reported the
presence of mutations in k-ras in stool of a patient eighteen
months before the appearance of a malignant polyp. Clearly
there are molecular changes occurring in the colon long
before the appearance of malignancies.
To summarize these studies, morphologically normal
colon mucosa in APCmin mice and in human cancer patients
is not metabolically normal. Altered gene expression in this
tissue does not appear to result from a ﬁeld eﬀect, because
there was no correlation between extent of altered regulation
and distance from polyp or tumor. Our data suggest that
alterations of expression levels of certain genes may be an
early event in carcinogenesis and may serve as a marker of
risk to development of colon cancer.
3.2. Altered Gene Expression in Individuals with Polyps. We
next examined whether these alterations in gene expression
patterns could also be observed in morphologically normal
colon mucosa of individuals with adenomatous polyps [22].
We analyzed a total of 169 rectosigmoid biopsies from 24
individuals with adenomatous/hyperplastic polyps versus
105 rectosigmoid biopsies from 17 control individuals with-
out polyps. The polyps were located in diﬀerent regions of
the colon, with 6 individuals presenting with a polyp in the
transverse region, 7 in the ascending/descending region, and
13 in the rectosigmoid area. All the biopsies of morpho-
l o g i c a l l yn o r m a lt i s s u ew e r et a k e nr a n d o m l ya n da w a yf r o m
the polyp, though we cannot rule out the possibility that, in
patients with a polyp in the rectosigmoid region, this polyp
had some eﬀect on metabolism in normal-appearing sur-
rounding tissue. Eight of the twenty-four patients with
polypswereindividualswitharelative(ﬁrst-orotherdegree)
with colon cancer, or with a personal history of colon cancer
or of some other form of cancer. However, none of the 17
control individuals had a known family or personal history
of cancer.
Todistinguishanyeﬀectsofpersonal/familyhistoryalone
from the presence of polyps, we initially carried out three
group-wise comparisons: (1) individuals with polyps and
no personal/family history versus controls, (2) individuals
with polyps and personal/family history versus controls, and
(3) individuals with polyps and personal/family history ver-
sus individuals with polyps and no history. The ﬁrst two
comparisons, individuals with polyps and with or without
history versus controls, were signiﬁcant, whereas there was
nosigniﬁcantdiﬀerenceingeneexpressionlevelsbetweenin-
dividuals with history and without history.
Further analysis was carried out on individual biopsies,
using the Mahalanobis measure. We compared the M-dist
for controls and for individuals with polyps, plotted on a
logarithmic scale. A log-rank test comparing the distribution
of all biopsies from individuals with polyps versus all con-
trols indicated a highly signiﬁcant diﬀerence (P<0.001).
Moreover, gene expression values above an M-dist value of
25 corresponded to the 95th percentile; that is, all values
abovethiscutoﬀweresigniﬁcantly(P<0.05)higherthanthe
pooledmeanofgeneexpressionvaluesofallcontrolbiopsies.
We found that 20/24 individuals with polyps had at least one
biopsy with a gene expression value above this cut-oﬀ point
(and 17 had two or more biopsies fulﬁlling this criterion)
versus 5/17 controls with one or more biopsies with a gene
expression value above the cutoﬀ (and just one control with
two biopsies meeting this criterion).
To summarize, this study found that normal-appearing
colon in individuals with polyps, like that we had previously
demonstrated in individuals with colon cancer, exhibited
altered levels of gene expression. Thus these changes occur
relatively early in the carcinogenetic process, before the ap-
pearance of an actual cancer.
3.3. Altered Gene Expression in Individuals with a Family
History of Cancer. Since our previous studies had indicated
thatthepresenceofeitheradenomatouspolypsorcoloncan-
cer in humans is associated with signiﬁcant alterations in the
expression of certain genes in the normal-appearing portion
of the colon, we next examined whether such changes exist
even in individuals with no polyps but possibly at risk for
cancer by virtue of a family history of the disease [23]. We
employed the same gene panel as in our previous studies,
except for the presence of an additional gene, serum amyloid
A1 (SAA1).
Twelve individuals with a family history of colon cancer
in a ﬁrst-degree relative and sixteen individuals with no
known family history of colon cancer were included in the
study. Biopsy samples of normal-appearing colon mucosa
were obtained from the ascending, transverse, descending,
and rectosigmoid regions of the colon (2–8 biopsy samples
were obtained from each region). Relative to normal con-
trols, the expression of several genes, including PPAR-γ,
SAA1, and IL-8 were signiﬁcantly altered in the macroscop-
ically normal rectosigmoid mucosa from individuals with a
familyhistory of coloncancer.Thus molecular abnormalities
that precede the appearance of adenomatous polyp are pre-
sentinthemucosaofindividualswhohaveafamilyhistoryof
colon cancer. This observation underscores the importance
of screening for individuals with family history of cancer, as
well as suggests the usefulness of this screen for individuals
who may be uncertain of their family history.
Multivariate analysis of the expression values of all
sixteen genes indicated a signiﬁcant diﬀerence in the biopsy
samples from the rectosigmoid region (P = 0.01) between
those with and those without a family history of sporadic
colon cancer. Gene expression in biopsy samples from the
descending, ascending, and transverse colon did not vary
signiﬁcantly between these two groups of individuals (P =
0.06, 0.22, and 0.52, resp.). Most of the diﬀerences in
rectosigmoid biopsy samples were contributed by just ﬁve
of these genes: PPAR-γ, SAA1, IL-8, COX-2, and PPAR-
δ. Similar to the alterations of gene expression in the
normal colon mucosa of cancer patients, we found that the
expression levels of IL-8 and COX-2 were upregulated, and
those of PPAR-γ and PPAR-δ were downregulated in the
mucosaofindividualswithafamilyhistoryofsporadiccolon
cancer.ISRN Gastroenterology 7
Table 4: Signiﬁcance of three groups versus controls for gene ex-
pression levels.
Comparison of overall
group
P values
Swabs Biopsies
Cancers versus controls <0.001 NA
Polyps versus controls <0.01 <0.01
FHSH versus controls <0.01 <0.01
3.4. Analysis of Gene Expression Using Rectal Swabs. The
studies discussed above demonstrate that morphologically
normal colon mucosa from individuals with colon cancer
or at increased risk for colon cancer have altered gene ex-
pression patterns, which could be the basis for screening.
However, all of the studies we have discussed to date involved
removal of biopsies during colonoscopy. Since the point of
developing a molecular screening process is to avoid the
necessity of colonoscopy, we next sought to develop a more
noninvasive way of obtaining colon mucosa samples. Using
an anoscope, we inserted a soft brush about 2cm. into the
colons of individuals and gently swabbed to remove colon
mucosal cells.
These cells were removed from the brush by dipping and
swirling it in a buﬀer. This was followed by extraction of
RNA, preparation of cDNA, and PCR. In this manner, we
compared rectal swabs with biopsies from 90 patients, who
included individuals with no polyps, but with family or per-
sonal history of cancer, individuals with adenomatous pol-
yps (with or without history), control individuals with
neither history nor polyps or colon cancers, and cancer pa-
tients.
Analysis of individuals with cancer, polyps, or family/
self-history of cancer clearly showed that gene expression
proﬁles of swab samples were very similar to proﬁles of sam-
ples obtained by biopsies (Table 4). All these groups of in-
dividuals were signiﬁcantly diﬀerent from a control group
withouthistoryorpolypswhenexpressionoftheentirepanel
of sixteen genes was analyzed multivariately. Moreover, a
large majority of individuals, ranging from about 70 to 84%,
exhibited signiﬁcantly diﬀerent expression values of swabs
compared to the pooled controls (Table 5).
Biopsy data showed comparable numbers (68–80%).
Thesedataindicatethatthesensitivityofourgeneexpression
analysis to detect individuals of cancer risk is quite high
if multiple rectal swabs are analyzed. Some patients in our
polyps’ group also had family history or self-history but no
subject in the family/self-history (FHSH) group had polyps.
This may have resulted in a higher percentage of signiﬁcantly
diﬀerent individuals in the polyps group than in the FHSH
group.
The cancer group was very small, consisting of just ﬁve
individuals. But gene expression analysis indicated that not
onlydidthecancergroupdiﬀersigniﬁcantlyfromthecontrol
group but each of ﬁve individuals was highly signiﬁcantly
diﬀe r e n tf r o mc o n t r o l sa sw e l l .T h eM - d i s tv a l u e so f4 8
out of 50 (96%) of our total swab samples from these ﬁve
individuals were above the 95th percentile line. This suggests
Table 5: Summary of patients with altered gene expression in three
groups versus control group.
Number of patients with altered gene expression
Swab samples Biopsy samples
Cancer (n = 5) 5/5 (100%) NA
Polyps (n = 25) 21/25 (84%) 20/25 (80%)
FHSH (n = 37) 26/37 (70%) 25/37 (68%)
a high sensitivity of this assay to identify individuals with
colon cancer, higher than has generally been reported using
stool analysis of gene mutations [4]. While this is a very
small number of subjects and will require studies with larger
patient pools, we reported similar results with seven addi-
tional colon cancer patients in our earlier studies using nor-
mal-appearing mucosal tissue taken from the margins of re-
sected colon cancer [8].
Furthermore, in one case, swabs were taken from an in-
dividual with cancer both before as well as after bowel pre-
paration. The altered gene expression proﬁle was highly sig-
niﬁcant in both instances. While further studies will be re-
quiredtosupportthisconclusion,thisresultsuggeststhatthe
rectal swab procedure may be able to dispense with bowel
preparation. This is another signiﬁcant disadvantage asso-
ciated with colonoscopy that undoubtedly contributes to
poor patient compliance, so eliminating it should further in-
crease the attractiveness of the swab procedure.
4. Conclusions
Ourstudiessuggestthatgeneexpressionanalysismaybesuit-
able as a screening process to identify individuals at risk
for developing colon cancer. While promising advances have
been made in the use of both DNA stool tests [3, 4]a n d
blood-borne biomarkers [5], none of these tests has yet
shown it is capable of equaling colonoscopy for sensitivity
and speciﬁcity, so diﬀerent approaches should continue. The
use of rectal swabs is a noninvasive procedure that can be
carriedoutinanydoctor’soﬃceandperhapsalsoathomeby
individuals with a properly prepared kit as is currently used
for fecal occult blood analysis. Moreover, Ahmed et al. [24]
were able to isolate RNA from stool samples and, using an
RT-PCR technique similar to ours, were able to distinguish
polyps and more advanced stages of colon cancer from each
other as well as from controls, in some cases by expression
of a single gene. Gene expression analysis can also be used in
certain blood tests for colon cancer [5]. Very recent work in
our own laboratory has suggested that these changes in gene
expressionmayalsobedetectedusingbuccal(cheek)swabs,a
still easier and less invasive procedure and that the technique
maybeapplicablefordetectingotherdiseasesassociatedwith
the gastrointestinal tract (Lee et al. “unpublished data”). So
gene expression analysis may have a wide spectrum of ap-
plications for cancer screening.
As applied to colon cancer, as we envision it, gene ex-
pression would not replace colonoscopy but allow its limited
resources to be focused on those individuals whom expres-
sion analysis indicates are most likely to have polyps. Given8 ISRN Gastroenterology
the large and growing variety of tests being explored, it may
bethatacombinationofmorethanonetypeoftestwillprove
to have the highest sensitivity to detection of cancer and
polyps. If individuals who are free of polyps and cancer can
be reliably identiﬁed without colonoscopy, it would result
in an enormous reduction of needed resources, for both
individuals and society.
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